POLD4

Across TCGA pan-cancer cohorts, POLD4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated POLD4 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher POLD4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated POLD4 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, UCEC, and LUAD are the cancer types where POLD4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.893	0.692	.011	15	view →
UCEC	OS	Tertile	All	0.765	0.976	.005	8	view →
LUAD	DFS	Median	II,III,IV	0.314	0.612	.023	8	view →
CCRCC	DFS	Median	III,IV	0.664	1.000	.003	7	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

POLD4–PDAC (DFS)

Open the PDAC breakdown →